Biogen acquires full control of Alzheimer's disease drug Aduhelm!

Compilenewborn

Recently, Biogen and Eisai jointly announced that the two parties have revised the existing cooperation agreement on the Alzheimer's disease (AD) drug aducanumab

According to an announcement issued by both parties, the amendment to the agreement will take effect on January 1, 2023, and Eisai will receive tiered royalties based on Aduhelm's net sales, rather than sharing global profits and losses

Overall, the two companies' economic arrangements for 2022 will remain substantially unchanged, with Eisai's share of expenses for the period January 1-December 31, 2022 capped at those related to the development, commercialization and manufacturing of Aduhelm the agreed amount

In addition, the two companies will continue to jointly develop and commercialize another AD monoclonal antibody, lecanemab, an investigational anti-amyloid beta (Aβ) fibrillar antibody that received U.

Eisai will continue to lead the development and regulatory submission of lecanemab globally, and the two companies will co-commercialize and co-promote the product, with Eisai having the final say

In addition, the supply agreement related to lecanemab has been extended from 5 years to 10 years

In response to this revision of the agreement, Biogen stated that this revised cooperation agreement will be able to improve operational efficiency and flexibility in response to market developments, including the US Centers for Medicare and Medicaid Services (CMS) finalization of Aduhelm health insurance coverage.

Reference source:

1.

2.